biblioteca virtual en salud

Búsqueda | Gripe por A(H1N1)

  • BIREME | OPAS | OMS logo
 

Historico de búsqueda  ()

Su selección  ()

 0 documento(s) seleccionado(s).

Refine su búsqueda

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (441)
Idioma
Año

Enviar por email

Ud. tiene 0 documento(s) seleccionado(s).

Ningún documento seleccionado

 
Resultados  1-12 de 657
1.

Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015.

Autor(es): Appiah, Grace D; Chaves, Sandra S; Kirley, Pam D; Miller, Lisa; Meek, James; Anderson, Evan; Oni, Oluwakemi; Ryan, Patricia; Eckel, Seth; Lynfield, Ruth; Bargsten, Marisa; Zansky, Shelley M; Bennett, Nancy; Lung, Krista; McDonald-Hamm, Christie; Thomas, Ann; Brady, Diane; Lindegren, Mary L; Schaffner, William; Hill, Mary; Garg, Shikha; Fry, Alicia M; Campbell, Angela P
Fuente: Clin Infect Dis;64(3): 364-367, 2017 Feb 01.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 28013261
Resumen: (See the Editorial Commentary by Martin on pages 368-9.)Using population-based surveillance data, we analyzed antiviral treatment among hospitalized patients with laboratory-confirmed influenza. Treatment increased after the influenza A(H1N1) 2009 pandemic from 72% in 2010-2011 to 89% in 2014-2015 (P < .001). Overall, treatment was higher in adults (86%) than in children (72%); only 56% of cases received antivirals on the day of admission.
3.

Homeopathy in disguise. Comment on Don et al.: Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.

Autor(es): Dueva, Evgenia V; Panchin, Alexander Y
Fuente: J Med Virol;2016 Dec 30.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 28036105
Resumen: The study «Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model¼ [Don et al., 2016] recently published in Journal of Medical Virology raises a number of concerns. We discuss these concerns in detail. This article is protected by copyright. All rights reserved.
4.

The phenomenon of released-activity. Reply on comment on Don et al.: Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.

Autor(es): Don, Elena S; Emelyanova, Alexandra G; Yakovleva, Natalia N; Petrova, Nataliia V; Nikiforova, Marina V; Gorbunov, Evgeniy A; Tarasov, Sergey A; Morozov, Sergey G; Epstein, Oleg I
Fuente: J Med Virol;2016 Dec 30.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 28036118
Resumen: This text is aimed to provide the readers with detailed information about phenomenon of released-activity and reply on the specific risen questions. This article is protected by copyright. All rights reserved.
5.

Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study.

Autor(es): Leung, Kathy; Lipsitch, Marc; Yuen, Kwok Yung; Wu, Joseph T
Fuente: Lancet Infect Dis;2016 Nov 30.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27914853
Resumen: BACKGROUND: Antivirals (eg, oseltamivir) are important for mitigating influenza epidemics. In 2007, an oseltamivir-resistant influenza seasonal A H1N1 strain emerged and spread to global fixation within 1 year. This event showed that antiviral-resistant (AVR) strains can be intrinsically more transmissible than their contemporaneous antiviral-sensitive (AVS) counterpart. Surveillance of AVR fitness is therefore essential. Our objective was to develop a simple method for estimating AVR fitne (mas)
6.

High antiviral effect of TiO ·PL-DNA nanocomposites targeted to conservative regions of (-)RNA and (+)RNA of influenza A virus in cell culture.

Autor(es): Levina, Asya S; Repkova, Marina N; Bessudnova, Elena V; Filippova, Ekaterina I; Mazurkova, Natalia A; Zarytova, Valentina F
Fuente: Beilstein J Nanotechnol;7: 1166-1173, 2016.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27826491
Resumen: The development of new antiviral drugs based on nucleic acids is under scrutiny. An important problem in this aspect is to find the most vulnerable conservative regions in the viral genome as targets for the action of these agents. Another challenge is the development of an efficient system for their delivery into cells. To solve this problem, we proposed a TiO ·PL-DNA nanocomposite consisting of titanium dioxide nanoparticles and polylysine (PL)-containing oligonucleotides. The TiO ·PL- (mas)
7.

Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.

Autor(es): Kossyvakis, A; Mentis, A-F A; Tryfinopoulou, K; Pogka, V; Kalliaropoulos, A; Antalis, E; Lytras, T; Meijer, A; Tsiodras, S; Karakitsos, P; Mentis, A F
Fuente: Eur J Clin Microbiol Infect Dis;2016 Nov 15.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27848039
Resumen: There was an increase in severe and fatal influenza cases in Greece during the 2011-2015 post-pandemic period. To investigate causality, we determined neuraminidase (NA) inhibitor susceptibility and resistance-conferring NA and hemagglutinin (HA) mutations in circulating influenza type A viruses during the pandemic (2009-2010) and post-pandemic periods in Greece. One hundred thirty-four influenza A(H1N1)pdm09 and 95 influenza A(H3N2) viruses submitted to the National Influenza Reference Lab (mas)
8.

Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.

Autor(es): Don, Еlena S; Emelyanova, Alexandra G; Yakovleva, Natalia N; Petrova, Nataliia V; Nikiforova, Marina V; Gorbunov, Evgeniy A; Tarasov, Sergey А; Morozov, Sergey G; Epstein, Оleg I
Fuente: J Med Virol;2016 Oct 21.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27769099
Resumen: The assessment of dose-response is an essential part of drug development in terms of the determination of a drug's effective dose, finding the safety endpoint, estimation of the pharmacokinetic profile, and even validation of drug activity, especially for therapeutic agents with a principally novel mechanism of action. Drugs based on released-active forms of antibodies are a good example of such a target. In this study, the efficacy of the antiviral drug Anaferon for children (released-acti (mas)
9.

Synthesis of Pyrazine-1,3-thiazine Hybrid Analogues as Antiviral Agent Against HIV-1, Influenza A (H1N1), Enterovirus 71 (EV71), and Coxsackievirus B3 (CVB3).

Autor(es): Wu, Hong-Min; Zhou, Kuo; Wu, Tao; Cao, Yin-Guang
Fuente: Chem Biol Drug Des;88(3): 411-21, 2016 Sep.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27062664
Resumen: A novel series of pyrazine-1,3-thiazine hybrid conjugates were synthesized in excellent yield. These derivatives were subsequently tested against human immunodeficiency virus (HIV-1); hemagglutinin type 1 and neuraminidase type 1-'influenza' A (H1N1) virus; enterovirus 71 (EV71); and coxsackievirus B3. The effect of these conjugates on the key enzymes responsible for the progression of these viral infections was also illustrated via enzyme-based assay, such as HIV-1 reverse transcriptase (R (mas)
10.

Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans.

Autor(es): To, Kelvin K W; Mok, Ka-Yi; Chan, Andy S F; Cheung, Nam N; Wang, Pui; Lui, Yin-Ming; Chan, Jasper F W; Chen, Honglin; Chan, Kwok-Hung; Kao, Richard Y T; Yuen, Kwok-Yung
Fuente: J Gen Virol;97(8): 1807-17, 2016 Aug.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27259985
Resumen: Immunomodulators have been shown to improve the outcome of severe pneumonia. We have previously shown that mycophenolic acid (MPA), an immunomodulator, has antiviral activity against influenza A/WSN/1933(H1N1) using a high-throughput chemical screening assay. This study further investigated the antiviral activity and mechanism of action of MPA against contemporary clinical isolates of influenza A and B viruses. The 50 % cellular cytotoxicity (CC50) of MPA in Madin Darby canine kidney cell l (mas)
11.

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.

Autor(es): Takashita, Emi; Ejima, Miho; Ogawa, Rie; Fujisaki, Seiichiro; Neumann, Gabriele; Furuta, Yousuke; Kawaoka, Yoshihiro; Tashiro, Masato; Odagiri, Takato
Fuente: Antiviral Res;132: 170-7, 2016 Aug.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27321665
Resumen: Favipiravir, a viral RNA-dependent RNA polymerase inhibitor, has recently been approved in Japan for influenza pandemic preparedness. Here, we conducted a cell-based screening system to evaluate the susceptibility of influenza viruses to favipiravir. In this assay, the antiviral activity of favipiravir is determined by inhibition of virus-induced cytopathic effect, which can be measured by using a colorimetric cell proliferation assay. To demonstrate the robustness of the assay, we compared (mas)
12.

Mycoplasma hyopneumoniae does not affect the interferon-related anti-viral response but predisposes the pig to a higher level of inflammation following swine influenza virus infection.

Autor(es): Deblanc, Céline; Delgado-Ortega, Mario; Gorin, Stéphane; Berri, Mustapha; Paboeuf, Frédéric; Berthon, Patricia; Herrler, Georg; Meurens, François; Simon, Gaëlle
Fuente: J Gen Virol;97(10): 2501-2515, 2016 Oct.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27498789
Resumen: In pigs, influenza A viruses and Mycoplasma hyopneumoniae (Mhp) are major contributors to the porcine respiratory disease complex. Pre-infection with Mhp was previously shown experimentally to exacerbate the clinical outcomes of H1N1 infection during the first week after virus inoculation. In order to better understand the interactions between these pathogens, we aimed to assess very early responses (at 5, 24 and 48 h) after H1N1 infection in pigs pre-infected or not with Mhp. Clinical sign (mas)
Resultados  1-12 de 657